Kayne Anderson Rudnick Investment Management
PTCT icon

Kayne Anderson Rudnick Investment Management’s PTC Therapeutics PTCT Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-44
Closed -$2K – 665
2022
Q1 		$2K Buy
+44
New +$1.7K ﹤0.01% 600
2021
Q1 		– Sell
-13
Closed -$1K – 693
2020
Q4 		$1K Buy
+13
New +$766 ﹤0.01% 654

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's PTCT Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of PTC Therapeutics (PTCT) in Q2 2022, closing a stake of 44 shares — an estimated $2K sold.

Kayne Anderson Rudnick Investment Management first reported a position in PTCT in Q4 2020 and held it in 2 quarters. The position peaked at $2K in Q1 2022. 181 funds tracked by Wall St. Rank hold PTCT as of Q2 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining PTC Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 44 PTC Therapeutics shares in Q2 2022, an estimated $2K.
  • Kayne Anderson Rudnick Investment Management first reported a position in PTC Therapeutics in Q4 2020 and held it in 2 quarters.
  • Kayne Anderson Rudnick Investment Management's PTC Therapeutics position peaked at $2K in Q1 2022.
  • 181 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.